ClinicalTrials.gg
CompletedNCT02653014Updated Dec 16, 2025

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

A Phase 1 interventional study of KBP-5074 in Healthy and Renal Insufficiency, sponsored by KBP Biosciences. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by KBP Biosciences · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2016, 10 years 5 months ago, and no results have been posted to the registry.
  • Registered 5 months after the study started (first participant enrolled Jul 2015, registered Dec 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 554 studies in Renal Insufficiency with a site in United States — 41 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
282nd of 469
26 · median 32
Started
2015
with 26 others
Phase 1
233 of 554
15 open now
Registered
316th of 554
by date

Among the 554 studies in Renal Insufficiency with a site in United States, this one is the 282nd largest by enrollment of the 469 interventional ones that give a count, is one of 27 that started in 2015, is one of 233 in phase 1, and was the 316th registered.

Renal Insufficiency

1,415 studies on the registry are indexed under Renal Insufficiency; 149 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

41 of the 554 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 94 Renal Insufficiency studies recruiting now, 49 (52%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 554 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This multiple ascending dose (MAD) study in healthy subjects and subjects with mild to moderate renal impairment will evaluate the safety, tolerability and pharmacokinetics of KBP-5074. Safety/tolerability data and Pharmacokinetics (PK)/Pharmacodynamics (PD) (plasma aldosterone, serum potassium, UACR and Blood Pressure) relationships will be explored to support the selection of dosing regimens of KBP-5074 that are suitable for the Phase II/III study.

Read the detailed description

This study consists of two parts: Part 1 is an open-label, multiple ascending dose (MAD) study to evaluate the safety, tolerability and pharmacokinetics of KBP-5074 in healthy subjects. The safety and tolerability will be assessed at each dose level before progressing to the next higher dose. Part 2 is an open label, randomized, parallel study to assess the safety and tolerability, the effect of renal dysfunction on the pharmacokinetics of KBP-5074, as well as the PK/PD relationship in subjects with mild to moderate renal impairment.

03

Conditions studied

  • Healthy
  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Part 1:

  • Healthy male or female subject
  • Are between the ages of 18 and 45 years (inclusive);
  • (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg.

Exclusion Criteria for Part 1:

  • history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug ;
  • Known or suspected ;
  • Positive blood screen for (HIV), surface antigen (HBsAg), or (HCV) antibody;
  • Positive pregnancy test result.

Inclusion Criteria for Part 2:

  • Are between the ages of 18 and 75 years (inclusive);
  • Mild to moderate chronic kidney disease (defined as estimated (eGFR) > 30 and ≤89 mL/min/1.73 m2, using the modification of diet in renal disease (MDRD) formula, for > 3 months;
  • Proteinuria (defined as urine albumin to creatinine ratio (UACR) ≥100 mg/g and ≤3,000 mg/g in two mid-morning urine specimens within a month interval);
  • Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
  • Serum potassium≥3.3 mmol/L and ≤4.8 mmol/L;
  • Body mass index (BMI) of 19 to 40 kg/m2 inclusive and body weight not less than 50 kg.

Exclusion Criteria for Part 2:

  • Severe uncontrolled hypertension (diastolic > 115 mmHg or systolic blood pressure > 180 mmHg) at either the Screening visit or the Study Check-in Visit;
  • Type I diabetes mellitus or poorly controlled Type 2 diabetes mellitus ( > 10%) at the Screening visit;
  • Prior kidney transplant, or anticipated need for transplant during study participation;
  • Clinical diagnosis of heart failure and persistent symptoms ( [NYHA] Class II- IV) at either the Screening visit or the Study Check-in Visit;
  • Known or suspected to study medications, including history of hypersensitivity or allergy to ACE inhibitors, ARBs, or aldosterone antagonists;
  • Any clinically significant disorder, except for conditions associated with type 2 diabetes mellitus history, which in the investigators opinion could interfere with the results of the trial;
  • Diabetic gastroparesis;
  • Known bilateral clinically relevant renal artery stenosis (>75% reduction in artery diameter).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Healthy Volunteers will receive 2.5mg of KBP-5074, QD, 14 days

    Drug: KBP-5074

  • Experimental
    Cohort 2

    Healthy Volunteers will receive 5.0mg of KBP-5074, QD, 14 days

    Drug: KBP-5074

  • Experimental
    Cohort 3

    Subjects with mild to moderate renal impairment will receive 0.5mg of KBP-5074, QD, 56 days

    Drug: KBP-5074

  • Experimental
    Cohort 4

    Subjects with mild to moderate renal impairment will receive 2.5mg of KBP-5074, QD, 56 days

    Drug: KBP-5074

Interventions

  • Also known as: mineralocorticoid receptor antagonist

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Rate of adverse events

    Time frame: Up to 69 days

Secondary outcomes

  1. Area Under Curve (AUC) in healthy subjects

    AUC 0-24 hours

    Time frame: pre-dose and 2, 4, 6, 8, 10, 12, 18, and 24 hours post dose on Day 1; pre-dose on Days 8, 11, 12, and 13; and pre-dose and 2, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 168, 216, 264, and 312 hours post dose on Day 14

  2. Area Under Curve (AUC) in subjects with mild to moderate renal impairment

    AUC 0-24 hours

    Time frame: pre-dose and 2, 4, 6, 8, 10, 12, 18, and 24 hours post dose on Day 1; pre-dose on Days 8, 11, 12, and 13; pre-dose and 2, 4, 6, 8, 10, 12, 18, and 24 hours post dose on Day 14; pre-dose on Days 29 and 43; and pre-dose and 6, 12, and 24 hours on Day 56

  3. The effect of mild to moderate renal impairment on the Area Under Curve (AUC)

    AUC 0-24 hours

    Time frame: Up to 15 days

  4. Plasma aldosterone levels in healthy subjects

    Plasma aldosterone level

    Time frame: Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Day 8; and 24 hours post last dose on Day 15

  5. Serum potassium levels in healthy subjects

    Serum potassium level

    Time frame: Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Day 8; and 24 hours post last dose on Day 15

  6. Plasma aldosterone levels in subjects with mild to moderate renal impairment

    Plasma aldosterone level

    Time frame: Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Days 8, 15, 29, and 43; and 24 hours post last dose on Day 57

  7. Serum potassium levels in subjects with mild to moderate renal impairment

    Serum potassium level

    Time frame: Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Days 8, 15, 29, and 43; and 24 hours post last dose on Day 57

  8. Urinary Albumin to Creatinine Ratio (UACR) in subjects with mild to moderate renal impairment

    Ratio of urinary albumin level to creatinine level

    Time frame: Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Days 8, 15, 29, and 43; and 24 hours post last dose on Day 57

  9. Blood Pressure in subjects with mild to moderate renal impairment

    Systolic and diastolic seated blood pressure

    Time frame: Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Days 8, 15, 29, and 43; and 24 hours post last dose on Day 57

07

Study locations

1 site
  • Research by Design, LLC
    Evergreen Park, Illinois 60805, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in May 2016, 9 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2015
First posted
Jan 12, 2016
StartActual
Jul 29, 2015
Primary completionActual
May 26, 2016
CompletionActual
Mar 28, 2017
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02653014
Lead sponsor
KBP Biosciences
Responsible party
Sponsor
First posted
Jan 12, 2016
Start date
Jul 29, 2015
Primary completion
May 26, 2016
Completion
Mar 28, 2017
Last update
Dec 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KBP-5074

Start the discussion